The Pharmabiotic Research Institute (PRI), Europe’s only regulatory expertise centre for the development of microbiome-based drug products, has announced the publication of a review titled “Live biotherapeutic products: the importance of a defined regulatory framework”. […]
A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics […]
LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) […]
A research team led by the University of Oklahoma has received a $3 million National Science Foundation grant to “understand the rules of life” through microbiome research. Microbiomes, a collection of microbes in a specific […]
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a collaboration with Boehringer Ingelheim to utilize the […]
Bacterial vaginosis (BV) is an imbalance of the vaginal microbiome that can lead to adverse health outcomes, including increased likelihood of potential pathogens colonizing the vagina, yet the mechanisms underlying these processes are poorly understood. […]
The word ‘synbiotic’ appears on a growing number of food and supplement products, with synbiotic ingredients showing promise for modulating the community of microbes living in the human gut, while providing a health benefit. Synbiotics […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today […]
Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, announced today that it has closed a $3 million seed financing round led by microbiome-focused investor, SymBiosis, LLC. The […]
Scioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche. Genome & Company is a leading microbiome company […]